BeStock  
Stocks › Biotechnology › EPRX

Eupraxia Pharmaceuticals EPRX

US equityMarket cap rank #3727Biotechnology
$7.78 +$0.04 (+0.52%)
Pre-market · Oct 8, 8:10 am ET · After hours $7.78 0.00%
Open$7.64
Prev close$7.74
Day range$7.48 – $7.88
Volume853.3K
Market cap$514.05M
P/E (TTM)–
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

Technical signals

Trend readLeaning bearish

3 bullish · 4 bearish of 7 signals

IndicatorValueSignalReading
Price vs 20-day average-4.6%BearishTrading below the 20-day average of $8.16
Price vs 50-day average+4.8%BullishTrading above the 50-day average of $7.42
Price vs 200-day average+5.8%BullishTrading above the 200-day average of $7.35
50-day vs 200-day50d above 200dBullishThe 50-day average is above the 200-day average
RSI (14)48.9BearishMomentum leans negative
MACD (12,26,9)0.08BearishMACD line is below its signal line
Bollinger band position27%BearishInside the 20-day bands

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

Levels & volatility

Moving averages

AverageLevelPrice vs. it
20-day SMA$8.16-4.6%
50-day SMA$7.42+4.8%
200-day SMA$7.35+5.8%

Recent price levels

LevelPrice
20-day high$9.21
20-day low$7.07
60-day high$9.21
60-day low$5.72
Upper Bollinger band$8.97
Lower Bollinger band$7.35

The 50-day average is currently 0.9% above the 200-day average — consistent with a “golden cross” (bullish) configuration.

30-day volatility94.3%
Average true range7.72% of price
Max drawdown (1y)-35.9%
Volume (10d vs 90d)2.62x

Discussion

No comments yet — be the first to weigh in on EPRX.

Leave a comment

Scroll to Top